- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06193954
VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions (VST100)
April 22, 2024 updated by: VasoStar, LLC
Evaluation of a Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions in Patients With Chronic Angina Refractory to Maximally Tolerated Guideline Directed Medical Therapy
The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
This Early Feasibility Study (EFS) is proposed to evaluate the initial safety and efficacy of the VasoStar guidewire system to cross complex coronary vascular lesions in non-tortuous arterial segments which are resistant to crossing with a traditional interventional guidewire.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mihaela Plesa
- Phone Number: 440 266 8226
- Email: mplesa@frantzgroup.com
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Principal Investigator:
- William Nicholson, MD
-
Contact:
- William Nicholson, MD
-
-
Ohio
-
Akron, Ohio, United States, 44034
- Summa Health
-
Contact:
- Kevin Silver, MD
-
Principal Investigator:
- Kevin Silver, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, over 18 years of age, presenting with at least one ischemia inducing lesion in a native coronary artery that is refractory to standard guidewire crossing. Chronic total occlusion (CTO) is defined as 100% coronary blockage for over a 3-month duration documented either by prior catheterization or by clinical evaluation
- Suitable candidate for non-emergent, coronary angioplasty
- Documented de-novo or restenotic coronary chronic total occlusion defined as a lesion with TIMI 0 flow for at least 90 days refractory to conventional guidewire crossing
- Left ventricle ejection fraction > 20% within the last 12 months.
- For antegrade chronic total occlusion procedures, activated clotting time (ACT) should be > 300 sec
- Chronic total occlusion in a non-tortuous arterial segment
- Voluntarily sign a Patient Informed Consent Form specific to the study.
- Physically and mentally willing to comply with all study requirements.
Exclusion Criteria:
- Successful target lesion crossing with a conventional wire system prior to enrollment
- Prisoners.
- Pregnancy
- Patient has an active implantable.
- Extensive dissection created by refractory guidewire
- Severe ongoing congestive heart failure (New York Heart Association Class IV symptoms)
- Active infection
- Uncontrolled Hypertension (Systolic blood pressure > 180 mm) at the time of the procedure
- History of severe reaction to contrast media
- Recent myocardial infarction (within 2 weeks)
- In-stent target lesion
- Severe cerebrovascular disease including history of prior stroke or transient ischemic attack within 1 month at the time of the procedure
- Saphenous vein graft (SVG) chronic total occlusion or an in-stent chronic total occlusion
- Short life expectancy due to other illnesses such as cancer or pulmonary, hepatic or renal disease
- Participation in another investigational protocol at the time of the procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VasoStar guidewire system
The VasoStar guidewire system will be used to cross vascular occlusion lesions.
|
The VasoStar Vibrational Guidewire System vibrates longitudinally at the distal segment of a 0.014" wire with an electromagnetic source to dissipate friction and probe an infinite number of points on the leading edge of the obstructive plaque.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with successful crossing of the target lesion with the VasoStar guidewire system
Time Frame: 1 day
|
Number of participants in whom the VasoStar guidewire successfully positioned in the distal vessel true lumen after initial failure to cross the target lesion with appropriate commercial standard workhorse wires
|
1 day
|
Incidence of Treatment-Emergent Serious Adverse Events
Time Frame: 30 days
|
Number of device- or procedure- related serious adverse events
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 13, 2024
Primary Completion (Estimated)
May 31, 2025
Study Completion (Estimated)
May 31, 2025
Study Registration Dates
First Submitted
December 21, 2023
First Submitted That Met QC Criteria
December 21, 2023
First Posted (Actual)
January 5, 2024
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- VST100
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Total Occlusion of Coronary Artery
-
University Hospital UlmRecruitingChronic Total Occlusion | Chronic Total Occlusion of Coronary ArteryGermany
-
Shanghai MicroPort Rhythm MedTech Co., Ltd.The First Affiliated Hospital of Nanchang University; Shanghai Zhongshan Hospital and other collaboratorsRecruitingChronic Total Occlusion of Coronary ArteryChina
-
Seung-Whan Lee, M.D., Ph.D.Medtronic; Abbott Medical Devices; Biotronik SE & Co. KG; Dio MedicalRecruitingChronic Total Occlusion of Coronary ArteryKorea, Republic of
-
Praxis Medical Devices LtdNot yet recruitingChronic Total Occlusion of Coronary Artery
-
Sandwell & West Birmingham Hospitals NHS TrustRecruiting
-
Amsterdam UMC, location VUmcRecruitingChronic Total Occlusion of Coronary ArteryNetherlands
-
Nitiloop Ltd.CompletedChronic Total Occlusion of Coronary ArteryUnited States, Poland
-
The First Affiliated Hospital with Nanjing Medical...RecruitingChronic Total Occlusion of Coronary ArteryChina
-
Assiut UniversityNational Taiwan University HospitalRecruitingChronic Total Occlusion of Coronary ArteryTaiwan
-
Shanghai 10th People's HospitalXijing HospitalNot yet recruitingChronic Total Occlusion of Coronary Artery
Clinical Trials on VasoStar guidewire system
-
Ziekenhuis Oost-LimburgCompletedAnomalies VascularBelgium
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Chinese University of Hong KongCompletedAbdominal Pain | Post-ERCP Acute PancreatitisChina
-
Lahey ClinicCompleted
-
Chinese Academy of Medical Sciences, Fuwai HospitalUnknownAtrial Septal DefectChina
-
Ajou University School of MedicineCompletedPancreatic Cancer | Bile Duct Cancer | Choledocholithiasis | Ampullary TumorKorea, Republic of
-
Institut universitaire de cardiologie et de pneumologie...Institut de Cardiologie de MontréalCompletedAortic Valve Stenosis | Aortic Valve Disease | Transcatheter Aortic Valve Replacement | Hemodynamic MeasurementCanada
-
Cordis CorporationCompletedCoronary Artery DiseaseGermany
-
Seoul National University HospitalCompleted
-
The Cleveland ClinicTerminatedCardiomyopathies | Congestive Heart FailureUnited States